Dupilumab - Prurigo nodularis
You are here : Home > Formulary Search > Dupilumab - Prurigo nodularis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Non Formulary
Formulations :
- Subcutaneous injection (sc)
Formulary Status :
Associated Icons :
NFD2
SPC
Restrictions / Comments :
Documents :
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Dupilumab
Indication :
Prurigo nodularis
Group Name :
Keywords :
Brand Names Include :
Dupixent
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that dupilumab for Prurigo Nodularis will be given a NON-FORMULARY traffic light status following publication of NICE TA955
Dupilumab is not recommended, by NICE, within its marketing authorisation, for treating this indication
Other Indications
Below are listed other indications that Dupilumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Prurigo nodularis.
- No records returned.